NCT06766500 - Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets

1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablet

DRUG

Synjardy® 5 mg/850 mg film-coated tablets

1 tablet of Empagliflozin+Metformin 5 mg/850 mg filmcoated tablets

Trial Locations (1)

"State Budgetary Institution of Healthcare of Yaroslavl region Yaroslavl Regional Clinical Narcological Hospital", Yaroslavl